

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
VIRTUAL PLATFORM**

July 19, 2023

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
<https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2023/DrSweetIntro.pdf>
- II. Roll Call
- III. Review of meeting transcript for April 19, 2023, meeting
https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2023/04-19-23_DURB_Meeting_Transcript_pdsdpd.pdf
- IV. Review of draft meeting summary for April 19, 2023, meeting
- V. Secretary's report
- VI. Old Business
 - A. MCO response to PA denials report
 - B. MCO churn rate request report
 - C. Utilization report on Leqembi (lecanemab-irmb) and Aduhelm (aducanumab-avwa)
 - D. Report on non-formulary denials of antidiabetic products
 - E. Hemgenix (etranacogene dezaparvovec-drlb) use in pediatric patients (CSL Behring/NJ PA)
 - F. Calcitonin gene-related peptide (CGRP) inhibitors utilization report (Q1 2022 vs. Q1 2023)
 - G. Summary of DURB suggested changes to proposed protocol (see link)
 - Livmarli (maralixibat)
<https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2023/LivmarliApprovedProtocol4-23.pdf>
- VII. New Business
 - A. Proposed protocol for Chimeric Antigen Receptor T cells (CAR T-cell) products
 - B. Proposed protocol for Qalsody (tofersen)
 - C. Proposed addendum to Biologic Receptor Modifiers (BRMs) for plaque psoriasis protocol
- VIII. A. Informational Highlights/Reports
 1. Gainwell Technologies/NJ MCO 1st Quarter 2023 Prior Authorization Report
 2. Summary of DURB Action Items
 3. (a) DHS, DHSS and MCO Programs Top Drugs Report/Physicians Administered Drugs (by amount paid and by category)
FFS top drugs:
https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2023/FFS_Top_Drugs_Report_May-2023.pdf

MCO top drugs:

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2023/MCO_Top_Drugs_Report_April-2023.pdf

FFS top drugs by category:

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2023/FFS_Top_Drugs_by_Category_May-2023.pdf

MCO top drugs by category:

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2023/MCO_Top_Drugs_by_Category_April-2023.pdf

(b) Antiviral drugs by amount paid

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2023/FFS_Antiviral_Drugs_May-2023.pdf

B. Medication information:

1. Weighing the Consequences of Weight-Loss Drugs
https://www.medpagetoday.com/opinion/second-opinions/104482?xid=nl_secondopinion_2023-05-14&eun=g2076570d0r
2. FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults
<https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults#:~:text=Today%2C%20the%20U.S.%20Food%20and,19%2C%20including%20hospitalization%20or%20death>
3. House Passes Bill to Address Fentanyl Overdoses
https://www.medpagetoday.com/washington-watch/washington-watch/104730?xid=nl_mpt_morningbreak2023-05-30&eun=g2076570d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=MorningBreak053023&utm_term=NL_Gen_Int_Daily_News_Update_active
4. COVID-19 Vaccines information
<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>
5. (Board members only). Medication Necessity Forms (MNFs) review for:
 - a) Skysona (elivaldogene autotemcel)
 - b) Zynteglo (betibeglogene autotemcel)